Cell-Free/JJ
miR-27a/NN
,/,
a/DT
Potential/JJ
Diagnostic/JJ
and/CC
Prognostic/JJ
Biomarker/NN
for/IN
Gastric/JJ
Cancer/NN
./.
====================
MicroRNAs/NNS
(/(
miRNAs/NNS
)/)
have/VBP
been/VBN
demonstrated/VBN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
carcinogenesis/NN
./.
====================
Previous/JJ
studies/NNS
revealed/VBD
that/IN
miRNAs/NNS
are/VBP
present/JJ
in/IN
human/JJ
plasma/NN
in/IN
a/DT
remarkably/RB
stable/JJ
form/NN
that/DT
is/VBZ
protected/VBN
from/IN
endogenous/JJ
RNase/NN
activity/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
measured/VBD
the/DT
plasma/NN
expression/NN
levels/NNS
of/IN
three/CD
miRNAs/NNS
(/(
miR-21/NN
,/,
miR-27a/NN
,/,
and/CC
miR-155/NN
)/)
to/TO
investigate/VB
the/DT
usefulness/NN
of/IN
miRNAs/NNS
for/IN
gastric/JJ
cancer/NN
detection/NN
./.
====================
We/PRP
initially/RB
examined/VBN
plasma/NN
miRNA/NN
expression/NN
levels/NNS
in/IN
a/DT
screening/NN
cohort/VBP
consisting/VBG
of/IN
15/CD
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
15/CD
healthy/JJ
controls/NNS
from/IN
Korean/JJ
population/NN
,/,
using/VBG
TaqMan/JJ
quantitative/JJ
real-time/NN
polymerase/NN
chain/NN
reaction/NN
./.
====================
We/PRP
observed/VBD
that/IN
the/DT
expression/NN
level/NN
of/IN
miR-27a/NN
was/VBD
significantly/RB
higher/JJR
in/IN
patients/NNS
with/IN
gastric/JJ
cancer/NN
than/IN
in/IN
healthy/JJ
controls/NNS
,/,
whereas/IN
the/DT
miR-21/NN
and/CC
miR-155a/NN
expression/NN
levels/NNS
were/VBD
not/RB
significantly/RB
higher/JJR
in/IN
the/DT
patients/NNS
with/IN
gastric/JJ
cancer/NN
./.
====================
Therefore/RB
,/,
we/PRP
further/RB
validated/VBN
the/DT
miR-27a/NN
expression/NN
level/NN
in/IN
73/CD
paired/JJ
gastric/JJ
cancer/NN
tissues/NNS
and/CC
in/IN
a/DT
validation/NN
plasma/NN
cohort/NN
from/IN
35/CD
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
35/CD
healthy/JJ
controls/NNS
./.
====================
In/IN
both/DT
the/DT
gastric/JJ
cancer/NN
tissues/NNS
and/CC
the/DT
validation/NN
plasma/NN
cohort/NN
,/,
the/DT
miR-27a/NN
expression/NN
levels/NNS
were/VBD
significantly/RB
higher/JJR
in/IN
patients/NNS
with/IN
gastric/JJ
cancer/NN
./.
====================
Receiver-operator/NN
characteristic/JJ
(/(
ROC/NN
)/)
analysis/NN
of/IN
the/DT
validation/NN
cohort/NN
,/,
revealed/VBD
an/DT
area/NN
under/IN
the/DT
ROC/NN
curve/JJ
value/NN
of/IN
0.70/CD
with/IN
75/CD
%/NN
sensitivity/NN
and/CC
56/CD
%/NN
specificity/NN
in/IN
discriminating/VBG
gastric/JJ
cancer/NN
./.
====================
Thus/RB
,/,
the/DT
miR-27a/NN
expression/NN
level/NN
in/IN
plasma/NN
could/MD
be/VB
a/DT
useful/JJ
biomarker/NN
for/IN
the/DT
diagnosis/NN
and/or/CC
prognosis/NN
of/IN
gastric/JJ
cancer/NN
./.
====================
In/IN
the/DT
past/NN
decade/NN
,/,
gastric/JJ
cancer/NN
has/VBZ
become/VBN
of/IN
the/DT
most/JJS
common/JJ
malignancies/NNS
worldwide/NN
./.
====================
Despite/IN
significant/JJ
improvements/NNS
in/IN
screening/VBG
and/CC
treatment/NN
technologies/NNS
for/IN
gastric/JJ
cancer/NN
,/,
it/PRP
remains/VBZ
the/DT
second/JJ
most/JJS
common/JJ
cause/VBP
of/IN
cancer-related/JJ
deaths/NNS
[/(
1/CD
]/)
./.
====================
An/DT
accurate/JJ
biomarker/NN
for/IN
detection/NN
of/IN
gastric/JJ
cancer/NN
may/MD
reduce/VB
the/DT
cancer-related/JJ
mortality/NN
./.
====================
Although/IN
conventional/JJ
strategies/NNS
for/IN
blood-based/VBN
biomarker/NN
discovery/NN
have/VBP
shown/VBN
promise/RB
,/,
the/DT
development/NN
of/IN
clinically/RB
validated/VBN
cancer/NN
detection/NN
markers/NNS
remains/VBZ
an/DT
unmet/JJ
challenge/NN
for/IN
many/JJ
common/JJ
human/JJ
cancers/NNS
[/(
2/CD
]/)
./.
====================
New/NN
approaches/NNS
that/WDT
can/MD
complement/VB
and/CC
improve/VBP
on/IN
current/JJ
strategies/NNS
for/IN
cancer/NN
detection/NN
are/VBP
urgently/RB
needed/VBD
./.
====================
MicroRNAs/NNS
(/(
miRNAs/NNS
)/)
are/VBP
a/DT
subset/NN
of/IN
non-coding/JJ
RNA/NN
molecules/NNS
(/(
approximately/RB
22/CD
nucleotide/NN
in/IN
length/NN
)/)
[/(
3/CD
]/)
that/IN
negatively/RB
regulate/VB
the/DT
protein/NN
expression/NN
of/IN
specific/JJ
mRNAs/NNS
by/IN
imperfectly/RB
base/NN
pairing/JJ
together/RB
,/,
resulting/VBG
in/IN
protein/NN
translational/JJ
repression/NN
of/IN
the/DT
target/NN
gene/NN
[/(
4/CD
]/)
./.
====================
Growing/VBG
evidence/NN
has/VBZ
shown/VBN
that/IN
miRNAs/NNS
are/VBP
involved/VBN
in/IN
a/DT
variety/NN
of/IN
biological/JJ
processes/NNS
,/,
including/VBG
cell/NN
proliferation/NN
,/,
differentiation/NN
,/,
and/CC
apoptosis/NN
[/(
567/CD
]/)
./.
====================
Studies/NNS
of/IN
miRNAs/NNS
have/VBP
been/VBN
extended/VBN
to/TO
many/JJ
kinds/NNS
of/IN
tumors/NNS
[/(
8/CD
]/)
because/IN
altered/JJ
expression/NN
of/IN
miRNAs/NNS
has/VBZ
been/VBN
demonstrated/VBN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
carcinogenesis/NN
,/,
either/CC
by/IN
oncogenic/JJ
[/(
910/CD
]/)
or/CC
tumor/NN
suppressor/NN
functions/NNS
[/(
1112/CD
]/)
./.
====================
For/IN
example/NN
,/,
three/CD
miRNAs/NNS
(/(
miR-21/NN
,/,
miR-27a/NN
,/,
and/CC
miR-155/NN
)/)
have/VBP
been/VBN
reported/VBN
as/IN
oncogenic/JJ
miRNAs/NNS
./.
====================
MiR-21/NN
,/,
the/DT
most/JJS
commonly/RB
up-regulated/VBN
miRNA/NN
in/IN
both/DT
solid/JJ
and/CC
hematological/JJ
tumor/NN
tissues/NNS
[/(
813/CD
]/)
,/,
directly/RB
targets/NNS
tumor/NN
suppressors/NNS
such/JJ
as/IN
PTEN/NN
phosphatase/NN
,/,
actin-binding/VBG
protein/NN
tropomyosin/NN
I/NN
and/CC
reversion-inducing-cysteine-rich/JJ
protein/NN
with/IN
Kazal/JJ
motif/NN
[/(
91415/CD
]/)
./.
====================
MiR-27a/NN
is/VBZ
an/DT
oncogenic/JJ
miRNA/NN
in/IN
gastric/JJ
adenocarcinoma/NN
,/,
targeting/VBG
prohibition/NN
[/(
16/CD
]/)
,/,
and/CC
genetic/JJ
variant/JJ
of/IN
miR-27a/NN
is/VBZ
associated/VBN
with/IN
its/PRP$
expression/NN
and/CC
increased/VBD
risk/NN
of/IN
various/JJ
cancer/NN
[/(
171819/CD
]/)
./.
====================
MiR-155/NN
is/VBZ
frequently/RB
overexpressed/VBN
in/IN
many/JJ
cancer/NN
tissues/NNS
and/CC
targets/NNS
tumor/NN
protein/NN
p53/NN
inducible/JJ
nuclear/JJ
protein/NN
1/CD
and/CC
FOXO3a/NN
[/(
2021/CD
]/)
./.
====================
Previously/RB
,/,
studies/NNS
revealed/VBD
that/IN
tumor-associated/JJ
miRNAs/NNS
are/VBP
present/JJ
in/IN
human/JJ
plasma/NN
and/CC
serum/NN
in/IN
a/DT
remarkably/RB
stable/JJ
form/VBP
that/DT
is/VBZ
protected/VBN
from/IN
endogenous/JJ
RNase/NN
activity/NN
[/(
2223/CD
]/)
,/,
and/CC
can/MD
be/VB
readily/RB
detected/VBN
in/IN
these/DT
blood/NN
fluids/NNS
[/(
242526/CD
]/)
./.
====================
In/IN
addition/NN
,/,
it/PRP
was/VBD
demonstrated/VBN
that/IN
the/DT
oncogenic/JJ
miRNA/NN
expression/NN
levels/NNS
in/IN
plasma/NN
and/CC
saliva/NN
were/VBD
decreased/VBN
in/IN
cancer/NN
patients/NNS
post-surgery/RB
[/(
27282930/CD
]/)
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
miRNAs/NNS
have/VBP
the/DT
potential/JJ
to/TO
be/VB
useful/JJ
diagnostic/JJ
or/CC
prognostic/JJ
biomarkers/NNS
for/IN
cancer/NN
detection/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
evaluated/VBD
the/DT
expression/NN
levels/NNS
of/IN
these/DT
three/CD
miRNA/JJ
variants/NNS
in/IN
plasma/NN
samples/NNS
from/IN
a/DT
screening/NN
cohort/VBP
of/IN
15/CD
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
15/CD
healthy/JJ
controls/NNS
in/IN
Korean/JJ
population/NN
./.
====================
The/DT
significant/JJ
miR-27a/NN
expression/NN
levels/NNS
found/VBD
were/VBD
further/RB
validated/VBN
in/IN
an/DT
additional/JJ
73/CD
paired/JJ
gastric/JJ
cancer/NN
tissues/NNS
and/CC
70/CD
plasma/NN
samples/NNS
from/IN
Korean/JJ
population/NN
,/,
using/VBG
quantitative/JJ
real-time/NN
polymerase/NN
chain/NN
reaction/NN
(/(
qRT-PCR/NN
)/)
./.
====================
Plasma/NN
and/CC
tissue/NN
samples/NNS
====================
The/DT
plasma/NN
and/CC
tissue/NN
samples/NNS
(/(
including/VBG
matched/VBN
non-tumor/JJ
tissues/NNS
)/)
from/IN
patients/NNS
with/IN
gastric/JJ
cancer/NN
were/VBD
retrieved/VBN
from/IN
the/DT
Chungnam/JJ
National/JJ
University/NN
Hospital/JJ
,/,
Republic/JJ
of/IN
Korea/NN
./.
====================
All/DT
patients/NNS
gave/VBD
their/PRP$
written/JJ
consent/NN
prior/JJ
to/TO
sample/JJ
collection/NN
./.
====================
The/DT
acquisition/NN
of/IN
clinical/JJ
material/JJ
was/VBD
approved/VBN
by/IN
the/DT
local/JJ
institution/NN
review/NN
board/JJ
./.
====================
These/DT
plasma/NN
samples/NNS
were/VBD
drawn/VBN
from/IN
35/CD
patients/NNS
(/(
18/CD
men/NNS
,/,
17/CD
women/NNS
)/)
with/IN
gastric/JJ
neoplasm/NN
and/CC
35/CD
control/NN
individuals/NNS
(/(
18/CD
men/NNS
,/,
17/CD
women/NNS
)/)
without/IN
neoplastic/JJ
disease/NN
./.
====================
There/EX
was/VBD
no/DT
significant/JJ
difference/NN
in/IN
age/NN
between/IN
the/DT
neoplastic/JJ
group/NN
(/(
51.80/CD
±/CD
11.88/CD
years/NNS
)/)
and/CC
the/DT
control/NN
group/NN
(/(
48.94/CD
±/CD
11.86/CD
years/NNS
)/)
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
The/DT
demographic/JJ
characteristics/NNS
of/IN
the/DT
subjects/NNS
who/WP
provided/VBD
the/DT
73/CD
paired/JJ
tissue/NN
samples/NNS
are/VBP
summarized/VBN
in/IN
Supplementary/JJ
Table/JJ
2/CD
./.
====================
Total/JJ
RNA/NN
extraction/NN
from/IN
fresh/JJ
tissues/NNS
and/CC
plasma/NN
====================
Venous/JJ
blood/NN
from/IN
all/DT
subjects/NNS
was/VBD
collected/VBN
into/IN
sterile/JJ
ethylenediamine/NN
tetracetic/JJ
aci-coated/JJ
vials/NNS
./.
====================
Within/IN
1/CD
h/NN
,/,
samples/NNS
were/VBD
centrifuged/JJ
(/(
2,000/CD
×g/JJ
,/,
10/CD
min/NN
)/)
,/,
following/VBG
which/WDT
the/DT
plasma/NN
was/VBD
removed/VBN
,/,
aliquoted/VBD
,/,
and/CC
stored/VBD
at/IN
-80℃/CD
until/IN
isolation/NN
of/IN
the/DT
circulating/VBG
RNA/NN
./.
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
300/CD
µL/NN
of/IN
plasma/NN
using/VBG
the/DT
Ambion/NN
PARIS/NN
Kit/NN
(/(
Ambion/NN
,/,
Austin/NN
,/,
TX/NN
,/,
USA/NN
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instruction/NN
./.
====================
Total/JJ
RNA/NN
from/IN
tissue/NN
samples/NNS
was/VBD
extracted/VBN
with/IN
the/DT
miRNeasy/NN
Midi/NN
Kit/NN
(/(
Qiagen/NN
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
and/CC
finally/RB
eluted/VBN
into/IN
80/CD
µL/NN
of/IN
elution/NN
solution/NN
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
The/DT
total/JJ
RNAs/NNS
isolated/VBN
from/IN
plasma/NN
and/CC
tissues/NNS
were/VBD
stored/VBN
at/IN
-80℃/CD
until/IN
further/RBR
use/NN
./.
====================
miRNA/NN
quantification/NN
in/IN
plasma/NN
====================
The/DT
miR-21/NN
,/,
miR-27a/NN
,/,
and/CC
miR-155/NN
expression/NN
levels/NNS
were/VBD
measured/VBN
by/IN
using/VBG
the/DT
TaqMan/NN
qRT-PCR/NN
analysis/NN
system/NN
(/(
Applied/VBN
Biosystem/NN
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
The/DT
expression/NN
level/NN
of/IN
each/DT
miRNA/NN
was/VBD
normalized/VBN
to/TO
U6snRNA/NN
./.
====================
In/IN
brief/JJ
,/,
this/DT
assay/NN
entailed/VBD
a/DT
2-step/JJ
qRT-PCR/NN
of/IN
miRNA/JJ
of/IN
19-25/CD
nucleotides/NNS
,/,
priming/VBG
with/IN
a/DT
stem-loop/JJ
primer/NN
onto/IN
a/DT
longer/RBR
cDNA/NN
that/IN
is/VBZ
amenable/JJ
to/TO
amplification/NN
,/,
and/CC
quantification/NN
by/IN
a/DT
TaqMan-based/JJ
real-time/VBP
PCR/NN
./.
====================
Ct/NN
was/VBD
the/DT
number/NN
of/IN
cycles/NNS
at/IN
which/WDT
the/DT
fluorescence/NN
signal/NN
passed/VBN
the/DT
appropriate/JJ
threshold/NN
./.
====================
Expression/NN
levels/NNS
were/VBD
determined/VBN
by/IN
using/VBG
the/DT
delta/NN
Ct/NN
(/(
ΔCt/NNP
)/)
method/NN
,/,
where/WRB
Ct/JJ
represents/VBZ
the/DT
number/NN
of/IN
cycles/NNS
in/IN
which/WDT
the/DT
fluorescence/NN
signal/NN
passed/VBN
the/DT
appropriate/JJ
threshold/JJ
./.
====================
miRNA/NN
quantification/NN
in/IN
tissue/NN
====================
For/IN
the/DT
detection/NN
of/IN
miRNA/JJ
,/,
2/CD
µg/JJ
of/IN
total/JJ
RNA/NN
extracted/VBN
from/IN
tissues/NNS
was/VBD
reverse/JJ
transcribed/VBN
into/IN
cDNA/NN
using/VBG
M-MLV/NN
(/(
Promega/NNP
,/,
Madison/NNP
,/,
WI/NN
,/,
USA/NNP
)/)
with/IN
miRNA-specific/JJ
stem-loop/JJ
primers/NNS
,/,
as/IN
previously/RB
described/VBN
[/(
16/CD
]/)
./.
====================
The/DT
cDNA/NN
was/VBD
used/VBN
for/IN
the/DT
amplification/NN
of/IN
mature/JJ
miR-27a/NN
and/CC
endogenous/JJ
control/NN
(/(
U6snRNA/NN
)/)
by/IN
real-time/NN
PCR/NN
./.
====================
The/DT
real-time/JJ
PCR/NN
was/VBD
performed/VBN
by/IN
using/VBG
the/DT
SYBR/NN
Green/NN
PCR/NN
Mix/NN
(/(
Bio-Rad/NNP
,/,
Hercules/NNS
,/,
CA/NNP
,/,
USA/NNP
)/)
with/IN
a/DT
CFX96/NN
real-time/VBP
PCR/NN
system/NN
(/(
Bio-Rad/NNP
)/)
./.
====================
The/DT
PCR/NN
cycles/NNS
were/VBD
as/IN
follows/VBZ
:/:
initial/JJ
denaturation/NN
at/IN
95℃/CD
for/IN
0.5/CD
min/NN
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
at/IN
94℃/CD
for/IN
0.5/CD
min/NN
,/,
56℃/CD
for/IN
1/CD
min/NN
,/,
72℃/CD
for/IN
0.5/CD
min/NN
./.
====================
The/DT
relative/JJ
miRNA/NN
expression/NN
level/NN
was/VBD
calculated/VBN
using/VBG
the/DT
delta/NN
Ct/NN
(/(
ΔCt/NNP
)/)
method/NN
./.
====================
Statistical/JJ
analysis/NN
====================
The/DT
significance/NN
of/IN
miRNA/JJ
expression/NN
level/NN
difference/NN
between/IN
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
cancer-free/JJ
control/NN
subjects/NNS
was/VBD
analyzed/VBN
using/VBG
Student/JJ
's/POS
t-test/JJS
./.
====================
Determination/NN
of/IN
the/DT
receiver-operator/NN
characteristic/JJ
(/(
ROC/NN
)/)
,/,
and/CC
the/DT
respective/JJ
area/NN
under/IN
the/DT
ROC/NN
curve/JJ
(/(
AUC/NN
)/)
,/,
and/CC
Kaplan-Meier/NN
survival/NN
analysis/NN
were/VBD
performed/VBN
using/VBG
the/DT
R/NN
software/RB
(/(
version/NN
2.6.1/CD
)/)
./.
====================
Results/NNS
with/IN
a/DT
p-value/JJ
of/IN
less/RBR
than/IN
0.05/CD
were/VBD
considered/VBN
significant/JJ
./.
====================
miR-21/NN
,/,
miR-27a/NN
,/,
and/CC
miR-155/NN
expression/NN
levels/NNS
in/IN
screening/NN
cohort/VBP
====================
To/TO
select/VB
potential/JJ
miRNAs/NNS
for/IN
gastric/JJ
cancer/NN
detection/NN
,/,
we/PRP
divided/VBD
our/PRP$
samples/NNS
into/IN
the/DT
30/CD
screening/NN
cohort/NN
and/CC
40/CD
validation/NN
cohort/NN
./.
====================
The/DT
expression/NN
levels/NNS
of/IN
three/CD
well-known/JJ
oncogenic/JJ
miRNAs/NNS
were/VBD
evaluated/VBN
in/IN
30/CD
plasma/NN
samples/NNS
consisting/VBG
of/IN
15/CD
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
15/CD
healthy/JJ
controls/NNS
./.
====================
Box/DT
plots/NNS
for/IN
the/DT
quantitative/JJ
fluorogenic/JJ
real-time/NN
PCR/NN
values/NNS
are/VBP
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
The/DT
miR-21/NN
and/CC
miR-155/NN
expression/NN
levels/NNS
were/VBD
not/RB
significantly/RB
different/JJ
between/IN
the/DT
neoplastic/JJ
group/NN
and/CC
the/DT
control/NN
(/(
p/NN
=/JJ
0.08/CD
and/CC
p/NN
=/JJ
0.27/CD
)/)
(/(
Fig/NN
./.
====================
1A/NN
and/CC
1C/NN
)/)
./.
====================
However/RB
,/,
the/DT
plasma/NN
miR-27a/NN
expression/NN
levels/NNS
were/VBD
significantly/RB
higher/JJR
in/IN
the/DT
patients/NNS
with/IN
gastric/JJ
cancer/NN
(/(
p/NN
=/JJ
0.002/CD
)/)
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Although/IN
miR-21/NN
expression/NN
level/NN
in/IN
plasma/NN
was/VBD
tend/VBN
to/TO
be/VB
increased/VBN
in/IN
patient/NN
with/IN
gastric/JJ
cancer/NN
compared/VBN
to/TO
healthy/JJ
control/JJ
(/(
p/NN
=/JJ
0.08/CD
)/)
,/,
we/PRP
selected/VBD
miR-27a/NN
as/IN
a/DT
high/JJ
priority/NN
for/IN
further/JJ
analysis/NN
./.
====================
miR-27a/NNS
expression/NN
level/NN
in/IN
paired/JJ
tissue/NN
samples/NNS
====================
We/PRP
examined/VBD
the/DT
miR-27a/NN
expression/NN
level/NN
in/IN
73/CD
paired/JJ
gastric/JJ
cancer/NN
tissues/NNS
to/TO
confirm/VB
the/DT
oncogenic/JJ
expression/NN
of/IN
this/DT
miRNA/NN
variant/JJ
./.
====================
The/DT
miR-27a/NN
expression/NN
level/NN
was/VBD
elevated/JJ
2.8-fold/JJ
in/IN
gastric/JJ
cancer/NN
tissues/NNS
compared/VBN
with/IN
non-tumor/JJ
tissues/NNS
(/(
p/NN
=/JJ
1.96e-06/CD
)/)
(/(
Fig/NN
./.
====================
2A/NN
)/)
,/,
and/CC
this/DT
miRNA/NN
was/VBD
highly/RB
expressed/VBN
in/IN
61/CD
out/RP
of/IN
73/CD
gastric/JJ
cancer/NN
patient/NN
samples/NNS
(/(
80/CD
%/NN
)/)
./.
====================
The/DT
miR-27a/NN
expression/NN
levels/NNS
were/VBD
highly/RB
elevated/JJ
in/IN
all/DT
stages/NNS
compared/VBN
with/IN
non-tumor/JJ
tissues/NNS
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
We/PRP
divided/VBD
the/DT
patient/NN
samples/NNS
into/IN
diffuse/JJ
and/CC
intestinal/JJ
types/NNS
,/,
based/VBN
on/IN
the/DT
Lauren/NN
classification/NN
,/,
because/IN
gastric/JJ
cancer/NN
patients/NNS
with/IN
diffuse-type/JJ
tumors/NNS
have/VBP
a/DT
much/RB
poorer/RB
prognosis/NN
than/IN
those/DT
with/IN
the/DT
intestinal/JJ
type/NN
./.
====================
We/PRP
observed/VBD
that/IN
the/DT
miR-27a/NN
expression/NN
levels/NNS
were/VBD
not/RB
significantly/RB
different/JJ
between/IN
intestinal/JJ
and/CC
diffuse/JJ
types/NNS
(/(
p/NN
=/JJ
0.19/CD
;/:
data/NNS
not/RB
shown/VBN
)/)
./.
====================
By/IN
ROC/NN
analysis/NN
,/,
we/PRP
observed/VBD
that/IN
the/DT
optimal/JJ
cut-off/JJ
value/NN
for/IN
discriminating/VBG
between/IN
patients/NNS
and/CC
healthy/JJ
individuals/NNS
was/VBD
0.0067/CD
for/IN
a/DT
miR-27a/NN
expression/NN
./.
====================
miR-27a/NNS
had/VBD
73/CD
%/NN
sensitivity/NN
and/CC
62/CD
%/NN
specificity/NN
in/IN
discriminating/VBG
gastric/JJ
cancer/NN
(/(
Fig/NN
./.
====================
2C/NN
)/)
./.
====================
Importantly/RB
,/,
we/PRP
observed/VBD
a/DT
significant/JJ
association/NN
between/IN
miR-27a/NN
overexpression/NN
and/CC
poor/JJ
survival/NN
(/(
p/NN
=/JJ
0.03/CD
)/)
(/(
Fig/NN
./.
====================
2D/CD
)/)
,/,
suggesting/VBG
that/IN
miR-27a/NN
has/VBZ
potential/JJ
to/TO
be/VB
used/VBN
as/IN
a/DT
prognostic/JJ
marker/NN
for/IN
patients/NNS
with/IN
gastric/JJ
cancer/NN
./.
====================
Taken/VBN
together/RB
,/,
the/DT
miR-27a/NN
expression/NN
pattern/NN
resembled/VBD
that/DT
of/IN
an/DT
oncogenic/JJ
microRNA/NN
and/CC
was/VBD
associated/VBN
with/IN
gastric/JJ
cancer/NN
patient/NN
survival/NN
./.
====================
MiR-27a/NN
expression/NN
level/NN
in/IN
validation/NN
cohort/NN
====================
To/TO
further/RBR
validate/NN
the/DT
diagnostic/JJ
value/NN
of/IN
miR-27a/NN
,/,
its/PRP$
expression/NN
level/NN
was/VBD
measured/VBN
in/IN
additional/JJ
plasma/NN
samples/NNS
drawn/VBN
from/IN
20/CD
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
20/CD
healthy/JJ
controls/NNS
./.
====================
The/DT
result/NN
of/IN
miR-27a/NN
expression/NN
data/NNS
obtained/VBN
from/IN
each/DT
15/CD
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
healthy/JJ
control/JJ
plasma/NN
samples/NNS
used/VBN
in/IN
screening/VBG
cohort/VBP
were/VBD
also/RB
included/VBD
in/IN
the/DT
validation/NN
cohort/NN
,/,
because/IN
of/IN
limited/JJ
sample/JJ
size/NN
./.
====================
The/DT
qRT-PCR/NN
results/NNS
revealed/VBD
that/IN
the/DT
miR-27a/NN
expression/NN
level/NN
was/VBD
highly/RB
elevated/JJ
in/IN
the/DT
neoplastic/JJ
group/NN
(/(
p/NN
=/JJ
0.009/CD
)/)
(/(
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
In/IN
both/DT
early/JJ
(/(
I/NN
and/CC
II/CD
)/)
and/CC
late/JJ
stages/NNS
(/(
III/CD
and/CC
IV/CD
)/)
,/,
the/DT
miR-27a/NN
expression/NN
levels/NNS
were/VBD
significantly/RB
higher/JJR
in/IN
the/DT
group/NN
with/IN
gastric/JJ
cancer/NN
(/(
Fig/NN
./.
====================
3B/NN
)/)
./.
====================
By/IN
ROC/NN
analysis/NN
,/,
we/PRP
observed/VBD
the/DT
AUC/NN
value/NN
to/TO
be/VB
0.70/CD
with/IN
75/CD
%/NN
sensitivity/NN
and/CC
56/CD
%/NN
specificity/NN
in/IN
discriminating/VBG
gastric/JJ
cancer/NN
based/VBN
on/IN
the/DT
cut-off/JJ
value/NN
of/IN
0.031/CD
for/IN
miR-27a/NN
expression/NN
level/NN
in/IN
plasma/NN
(/(
Fig/NN
./.
====================
3C/NN
)/)
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
the/DT
plasma/NN
miR-27a/NN
expression/NN
level/NN
may/MD
have/VB
potential/JJ
as/IN
a/DT
non-invasive/JJ
diagnostic/JJ
biomarker/NN
for/IN
gastric/JJ
cancer/NN
./.
====================
A/DT
diagnostic/JJ
source/NN
that/DT
would/MD
provide/VB
high/JJ
specificity/NN
and/CC
sensitivity/NN
may/MD
be/VB
of/IN
enormous/JJ
benefit/VB
to/TO
cancer/NN
patients/NNS
,/,
particularly/RB
if/IN
the/DT
biosource/NN
could/MD
be/VB
obtained/VBN
from/IN
non-invasive/JJ
materials/NNS
./.
====================
It/PRP
was/VBD
demonstrated/VBN
that/IN
miRNAs/NNS
are/VBP
involved/VBN
in/IN
multiple/JJ
steps/NNS
of/IN
carcinogenesis/NN
,/,
either/CC
by/IN
oncogenic/JJ
or/CC
tumor/NN
suppressor/NN
functions/NNS
[/(
31/CD
]/)
,/,
and/CC
circulating/VBG
miRNAs/NNS
exist/VBP
in/IN
the/DT
serum/NN
or/CC
plasma/NN
[/(
293233/CD
]/)
./.
====================
More/RBR
importantly/RB
,/,
miRNAs/NNS
have/VBP
been/VBN
detected/VBN
in/IN
human/JJ
serum/NN
and/CC
plasma/NN
in/IN
stable/JJ
forms/NNS
because/IN
of/IN
their/PRP$
short/JJ
hairpin/NN
structures/NNS
,/,
encapsulation/NN
by/IN
microvesicles/NNS
,/,
and/CC
association/NN
with/IN
protein/NN
complexes/NNS
[/(
22233435/CD
]/)
./.
====================
Thus/RB
,/,
the/DT
detection/NN
of/IN
any/DT
altered/JJ
expression/NN
of/IN
tumor-specific/JJ
miRNAs/NNS
in/IN
saliva/NN
,/,
serum/NN
,/,
plasma/NN
,/,
and/CC
urine/NN
may/MD
offer/VB
a/DT
promising/JJ
approach/NN
for/IN
non-invasive/JJ
gastric/JJ
cancer/NN
detection/NN
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
plasma/NN
expression/NN
levels/NNS
of/IN
three/CD
miRNAs/NNS
(/(
miR-21/NNS
,/,
miR-27a/NN
,/,
and/CC
miR-155/NN
)/)
were/VBD
measured/VBN
in/IN
a/DT
screening/NN
cohort/VBP
,/,
and/CC
we/PRP
observed/VBD
that/IN
miR-27a/NN
expression/NN
was/VBD
significantly/RB
elevated/JJ
in/IN
gastric/JJ
cancer/NN
samples/NNS
compared/VBN
with/IN
healthy/JJ
control/JJ
samples/NNS
./.
====================
Our/PRP$
result/NN
is/VBZ
similar/JJ
to/TO
previously/RB
reported/VBD
results/VBZ
[/(
36/CD
]/)
./.
====================
Next/RB
,/,
we/PRP
investigated/VBD
whether/IN
plasma/NN
miR-27a/NN
could/MD
be/VB
released/VBN
from/IN
gastric/JJ
tumor/NN
tissues/NNS
./.
====================
We/PRP
observed/VBD
that/IN
the/DT
miR-27a/NN
expression/NN
level/NN
was/VBD
similar/JJ
between/IN
gastric/JJ
tumor/NN
tissues/NNS
and/CC
plasma/NN
,/,
suggesting/VBG
that/IN
the/DT
plasma/NN
miR-27a/NN
expression/NN
level/NN
may/MD
reflect/VB
that/DT
of/IN
the/DT
gastric/JJ
tumor/NN
tissues/NNS
./.
====================
miR-27a/NNS
is/VBZ
located/JJ
on/IN
chromosome/NN
19/CD
,/,
and/CC
has/VBZ
oncogenic/JJ
function/NN
in/IN
gastric/JJ
adenocarcinoma/NN
,/,
by/IN
targeting/VBG
prohibition/NN
[/(
16/CD
]/)
./.
====================
This/DT
miRNA/NN
variant/JJ
is/VBZ
associated/VBN
with/IN
lymph/NN
node/NN
metastasis/NN
and/CC
is/VBZ
overexpressed/VBN
in/IN
gastric/JJ
cancer/NN
[/(
17/CD
]/)
./.
====================
In/IN
addition/NN
,/,
miR-27a/NN
can/MD
regulate/VB
tumor/NN
suppress/VBP
genes/NNS
such/JJ
as/IN
SPRY2/NN
,/,
and/CC
FBW7/NN
[/(
3738/CD
]/)
./.
====================
SPRY2/NN
can/MD
inhibit/VB
tumor/NN
growth/NN
and/CC
metastases/NNS
by/IN
interfering/VBG
with/IN
Ras/MAPK/NN
activation/NN
[/(
37/CD
]/)
,/,
and/CC
FBW7/NN
acts/VBZ
as/IN
the/DT
substrate/NN
recognition/NN
component/NN
of/IN
a/DT
Skp1-Cul1-F-box-protein/JJ
ubiquitin/NN
ligase/NN
that/DT
targets/VBZ
numerous/JJ
oncoproteins/NNS
for/IN
proteasomal/JJ
degradation/NN
[/(
38/CD
]/)
./.
====================
Growing/VBG
evidence/NN
has/VBZ
suggested/VBN
that/IN
miR-27a/NN
has/VBZ
an/DT
important/JJ
role/NN
in/IN
gastric/JJ
cancer/NN
development/NN
and/CC
progression/NN
./.
====================
To/TO
estimate/VB
its/PRP$
potential/JJ
value/NN
for/IN
gastric/JJ
cancer/NN
detection/NN
,/,
we/PRP
evaluated/VBD
the/DT
plasma/NN
miR-27a/NN
expression/NN
level/NN
in/IN
a/DT
validation/NN
cohort/NN
consisting/VBG
of/IN
35/CD
patients/NNS
with/IN
gastric/JJ
cancer/NN
and/CC
35/CD
healthy/JJ
control/JJ
samples/NNS
./.
====================
The/DT
sensitivity/NN
for/IN
the/DT
validation/NN
cohort/NN
was/VBD
estimated/VBN
as/IN
75/CD
%/NN
and/CC
the/DT
specificity/NN
as/IN
56/CD
%/NN
./.
====================
Current/JJ
diagnostic/JJ
tools/NNS
for/IN
gastric/JJ
cancer/NN
,/,
such/JJ
as/IN
the/DT
serological/JJ
markers/NNS
carbohydrate/VBP
antigen/NN
19-9/CD
and/CC
carcinoembryonic/JJ
antigen/NN
have/VBP
low/JJ
specificity/NN
and/CC
sensitivity/NN
[/(
36/CD
]/)
./.
====================
Our/PRP$
data/NNS
indicates/VBZ
that/IN
the/DT
sensitivity/NN
and/CC
specificity/NN
of/IN
plasma/NN
miR-27a/NN
are/VBP
better/RBR
than/IN
that/DT
of/IN
the/DT
serological/JJ
markers/NNS
,/,
although/IN
plasma/NN
miR-27a/NN
alone/RB
is/VBZ
not/RB
sufficient/JJ
for/IN
accurate/JJ
gastric/JJ
cancer/NN
detection/NN
./.
====================
Thus/RB
,/,
real/JJ
improvement/NN
in/IN
the/DT
accuracy/NN
of/IN
gastric/JJ
cancer/NN
detection/NN
still/RB
needs/VBZ
to/TO
be/VB
achieved/VBN
by/IN
recruiting/VBG
additional/JJ
plasma/NN
miRNA/NN
markers/NNS
./.
====================
In/IN
conclusion/NN
,/,
plasma/NN
miR-27a/NN
could/MD
be/VB
a/DT
useful/JJ
non-invasive/JJ
biomarker/NN
for/IN
gastric/JJ
cancer/NN
detection/NN
./.
====================
Additional/JJ
studies/NNS
using/VBG
a/DT
large/JJ
cohort/JJ
of/IN
samples/NNS
are/VBP
needed/VBN
to/TO
validate/VB
these/DT
results/NNS
because/IN
our/PRP$
study/NN
had/VBD
a/DT
small/JJ
sample/NN
size/NN
./.
====================
Expression/NN
levels/NNS
of/IN
three/CD
miRNAs/NNS
in/IN
the/DT
screening/NN
cohort/NN
./.
====================
miR-21/NN
(/(
A/NN
)/)
,/,
miR-27a/NN
(/(
B/NN
)/)
,/,
and/CC
miR-155/NN
(/(
C/NN
)/)
./.
====================
The/DT
expression/NN
level/NN
of/IN
each/DT
miRNA/NN
was/VBD
normalized/VBN
to/TO
U6snRNA/NN
./.
====================
miR-27a/NNS
expression/NN
level/NN
in/IN
paired/JJ
gastric/JJ
cancer/NN
tissues/NNS
./.
====================
(/(
A/NN
)/)
Box/NN
plot/NN
of/IN
miR-27a/NN
expression/NN
level/NN
(/(
n=/JJ
73/CD
)/)
./.
====================
(/(
B/NN
)/)
MiR-27a/NN
expression/NN
level/NN
by/IN
TNM/NN
stage/NN
./.
====================
(/(
C/NN
)/)
The/DT
receiver-operator/NN
characteristic/JJ
curve/JJ
and/CC
area/NN
under/IN
the/DT
receiver-operator/NN
characteristic/JJ
curve/JJ
(/(
AUC/NN
)/)
value/NN
were/VBD
estimated/VBN
using/VBG
R/NN
software/RB
./.
====================
The/DT
miR-27a/NN
expression/NN
level/NN
was/VBD
normalized/VBN
to/TO
U6snRNA/NN
./.
====================
(/(
D/NN
)/)
Kaplan-Meier/NN
analysis/NN
of/IN
patient/NN
survival/NN
based/VBN
on/IN
miR-27a/NN
expression/NN
in/IN
gastric/JJ
tumors/NNS
./.
====================
The/DT
log-rank/NN
test/NN
was/VBD
used/VBN
to/TO
compare/VB
survival/NN
between/IN
the/DT
low-/JJ
and/CC
high-/JJ
miR-27a/NN
expression/NN
groups/NNS
of/IN
patients/NNS
on/IN
the/DT
basis/NN
of/IN
average/JJ
miR-27a/NN
expression/NN
./.
====================
Plasma/NN
miR-27a/NN
expression/NN
levels/NNS
in/IN
the/DT
validation/NN
cohort/NN
./.
====================
(/(
A/NN
)/)
Box/NN
plot/NN
of/IN
plasma/NN
miR-27a/NN
expression/NN
level/NN
./.
====================
(/(
B/NN
)/)
MiR-27a/NN
expression/NN
by/IN
TNM/NN
stage/NN
./.
====================
(/(
C/NN
)/)
Receiver-operator/NN
characteristic/JJ
(/(
ROC/NN
)/)
curve/VBP
analysis/NN
using/VBG
the/DT
plasma/NN
miR-27a/NN
expression/NN
level/NN
./.
====================
The/DT
plasma/NN
miR-27a/NN
marker/NN
yielded/VBD
an/DT
area/NN
under/IN
the/DT
ROC/NN
curve/JJ
(/(
AUC/NN
)/)
of/IN
0.70/CD
with/IN
75/CD
%/NN
sensitivity/NN
and/CC
56/CD
%/NN
specificity/NN
in/IN
discriminating/VBG
gastric/JJ
cancer/NN
./.
====================
